Pear Therapeutics Profit Margin

Pear Therapeutics posts a profit margin of 195.19% as of December 2022. That compares with -2220.12% in the prior-year period — up 108.8% year over year. That is above the sector sector average of 13.2%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Pear Therapeutics's profit margin was -2220.12%. The latest reading is 195.19% — a 108.8% year-over-year increase (period ending December 2022). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a profit margin near 13.2% is typical. Pear Therapeutics's 195.19% is higher that level. That is roughly 1378.8% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Pear Therapeutics's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 195.19% as of December 2022; use YoY and peer views to separate noise from signal.

Context for PEAR's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.2%), and (3) consistency with growth and profitability. This page covers the first two; Pear Therapeutics's other metric pages and overview cover the third.